Nauta Alma J, Fibbe Willem E
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Blood. 2007 Nov 15;110(10):3499-506. doi: 10.1182/blood-2007-02-069716. Epub 2007 Jul 30.
Mesenchymal stem cells (MSCs) are multipotential nonhematopoietic progenitor cells capable of differentiating into multiple lineages of the mesenchyme. MSCs have emerged as a promising therapeutic modality for tissue regeneration and repair. Further clinical interest has been raised by the observation that MSCs are immunoprivileged and, more importantly, display immunomodulatory capacities. Although the mechanisms underlying the immunosuppressive effects of MSCs have not been clearly defined, their immunosuppressive properties have already been exploited in the clinical setting. The aim of this review is to critically discuss the immunogenicity and immunomodulatory properties of MSCs, both in vitro and in vivo, the possible underlying mechanisms, the potential clinical use of MSCs as modulators of immune responses in vivo, and to indicate clinical safety concerns and recommendations for future research.
间充质干细胞(MSCs)是多能非造血祖细胞,能够分化为间充质的多个谱系。MSCs已成为一种有前景的组织再生和修复治疗方式。观察到MSCs具有免疫特权,更重要的是具有免疫调节能力,这进一步引发了临床兴趣。尽管MSCs免疫抑制作用的潜在机制尚未明确界定,但其免疫抑制特性已在临床环境中得到利用。本综述的目的是批判性地讨论MSCs在体外和体内的免疫原性和免疫调节特性、可能的潜在机制、MSCs作为体内免疫反应调节剂的潜在临床应用,并指出临床安全性问题以及对未来研究的建议。